Loading content…
Affiliate-supportedIndependent editorialWe never sell medicationSee how
Live tracker
Reviewed June 13, 2026. Every item below is dated and linked to a primary source.
As of June 13, 2026: the Wegovy pill (oral semaglutide) and Lilly's Foundayo (orforglipron) are both FDA-approved oral GLP-1s for weight loss; retatrutide is not approved yet (Phase 3, ~28% weight loss); generic liraglutide is now on the market; and the FDA has proposed permanently ending mass GLP-1 compounding, with public comments open through June 29, 2026.
No — retatrutide is not FDA-approved as of June 2026. Lilly’s triple-agonist posted ~28% average weight loss in Phase 3 (TRIUMPH-1, 28.3% at 80 weeks, reported May 21, 2026), but no New Drug Application has been filed; submission is expected in Q4 2026 with approval likely in late 2027.
Retatrutide (GLP-1 / GIP / glucagon) shows the largest weight loss of any GLP-1-class agent in trials so far. Until it is approved and launched (realistically 2028), the available options remain semaglutide and tirzepatide products — anything sold as “retatrutide” today is not an FDA-approved medicine.
Today’s strongest approved option: tirzepatideOn April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them. Public comments are open through June 29, 2026.
Both shortages are long resolved (tirzepatide December 2024, semaglutide February 21, 2025), so the legal basis for large-scale compounding is closing. If finalized, compounded GLP-1 access narrows sharply — confirm any compounded plan’s status with the provider before committing.
Compounded semaglutide — current status & costYes — the FDA approved Eli Lilly’s Foundayo (orforglipron) on April 1, 2026 for adults with obesity or overweight with weight-related conditions. It is the first oral GLP-1 pill for weight loss with no food, water, or time-of-day restrictions.
A once-daily non-peptide pill that achieved ~12% average weight loss at the highest dose over 72 weeks. Available via LillyDirect and retail/telehealth: about $149/mo self-pay for the lowest dose, as low as $25/mo with commercial insurance and the savings card, and $50/mo for eligible Medicare Part D from July 1, 2026.
Compare oral vs injectable tirzepatide costYes — the FDA approved the Wegovy pill (oral semaglutide 25 mg, once daily) on December 22, 2025, the first oral GLP-1 approved for weight management. It launched in the U.S. in early January 2026.
In the OASIS 4 trial oral semaglutide 25 mg delivered 16.6% mean weight loss when taken as directed, and it is also approved to reduce major cardiovascular events. Novo Nordisk set self-pay pricing around $149/mo, with insured copays that can fall to ~$25. The pill requires a 30-minute wait before eating, drinking, or other medicines.
Estimate your Wegovy costGeneric liraglutide is now available: the FDA approved the first generic of Saxenda (weight management) in August 2025, after Teva’s authorized generic of Victoza (diabetes) in June 2024. It is the first generic GLP-1 to reach the U.S. market.
Brand Saxenda runs $1,300–$1,800/mo cash; generic liraglutide has fallen as low as ~$230/mo at some pharmacies. More manufacturers were cleared to enter after February 24, 2026, which should push prices down further. Liraglutide is a daily injection and less potent than semaglutide/tirzepatide — but it is now the cheapest brand-equivalent GLP-1 route.
Saxenda (liraglutide) — providers & costYes. The FDA approved the Wegovy pill (oral semaglutide 25 mg, once daily) on December 22, 2025 — the first oral GLP-1 approved for weight management. It launched in early January 2026 at roughly $149/mo self-pay.
Yes. The FDA approved Eli Lilly’s Foundayo (orforglipron) on April 1, 2026 — the first oral GLP-1 weight-loss pill with no food, water, or time-of-day restrictions, with ~12% average weight loss in trials.
No. As of June 2026 retatrutide is not approved and no application has been filed. Phase 3 showed ~28% weight loss; an FDA submission is expected in Q4 2026 and approval likely in late 2027.
For now, but access is narrowing. With both shortages resolved, the FDA proposed on April 30, 2026 to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list; public comments run through June 29, 2026. Confirm current status with any provider before committing.
Pick a medication to see providers, cost, and savings.
GLP1Zoom is an affiliate-only comparator. This page summarizes publicly-reported regulatory and market events with primary sources; it is not medical advice. Drug approvals, prices, and supply change quickly — always confirm current status with the manufacturer, the FDA, or your prescriber.